10-Q · May 5, 2026
Theriva Biologics reported a significant improvement in its financial performance for Q1 2026, with revenue of $300,000 and a narrower net loss of $2.0 million ($0.05 per share), compared to a net loss of $4.3 million…
Earnings analysis · 10-Q
TOVX earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Theriva Biologics reported a Q2 2026 EPS loss of $0.07, missing the $0.05 consensus loss estimate, while the filing excerpt does not provide current-quarter revenue, margin, segment, or free-cash-flow figures. Liquidity…
Read full summary
Theriva Biologics reported a Q2 2026 EPS loss of $0.07, missing the $0.05 consensus loss estimate, while the filing excerpt does not provide current-quarter revenue, margin, segment, or free-cash-flow figures. Liquidity deteriorated, with cash of approximately $11.3 million and working capital of $1.6 million at June 30, 2026, versus $13.1 million and $7.5 million, respectively, at December 31, 2025. Management expects cash to fund operations only into Q1 2027, is prioritizing VCN-01, and continues to disclose substantial going-concern uncertainty and a need for additional financing.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.07
What stood out
-
Disclosure controls remain effective
Management reported that disclosure controls and procedures were effective as of June 30, 2026, and stated that no changes during the three months ended June 30, 2026 materially affected internal control over financial reporting.
-
Cash runway extends into Q1 2027
The company stated that cash and cash equivalents were approximately $11.3 million at June 30, 2026 and that current cash is expected to fund operations into the first quarter of 2027.
-
Capital focused on VCN-01
Management intends to focus capital on VCN-01 clinical trials while limiting internal funding for SYN-004, and said existing cash should support commencement of a Phase 2a VCN-01 study and regulatory interactions for a proposed retinoblastoma pivotal trial.
What to watch
-
Going-concern and liquidity risk
The company disclosed substantial doubt about its ability to continue as a going concern for the next twelve months, citing recurring operating losses and the need for additional financing. Cash declined from approximately $13.1 million at December 31, 2025 to $11.3 million at June 30, 2026, while working capital fell from $7.5 million to $1.6 million.
-
Additional capital is required
Operating activities used approximately $5.5 million of net cash during the six months ended June 30, 2026. The company said it may need additional equity or debt financing and warned that failure to obtain funding could delay, reduce or eliminate development programs; equity financing may also cause significant dilution.
-
Deferred $5.0 million milestone
An additional $5.0 million VCN-01 milestone payment has been earned but deferred pending discussions with Grifols. The company warned that payment of this amount would significantly deplete cash and could impair its ability to fund operations and clinical research.
-
Strategic-alternative execution risk
The company newly identified strategic alternatives including an acquisition, merger, reverse merger, business combination or asset sale, but warned that no transaction may occur on favorable terms or within an advantageous timeframe. It also stated that failure to complete a strategic alternative could cause a decline in the common-stock price.
-
Clinical program constraints
Management stated that current cash may not be sufficient for additional VCN-01 trials beyond the planned Phase 2a study, additional SYN-004 trials, or completion of the last cohort of the SYN-004 Phase 1a/2a trial. A broad-indication Phase 3 SYN-004 program is not currently feasible without a partner because of capital constraints.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management stated that current cash is expected to fund operations into the first quarter of 2027; the company expects to focus capital on VCN-01 and does not intend to provide further internal funding for SYN-004 development.
Earlier filings 4
10-K · March 12, 2026
Theriva Biologics has re‑focused into oncology following its March 2022 acquisition of VCN and centers its strategy on advancing the oncolytic adenovirus VCN‑01 (intravenous and intravitreal delivery) while monetizing…
10-Q · August 11, 2025
Theriva Biologics reported no revenue and a Q2 2025 net loss of $13,058,000 (EPS -$1.93), larger in dollars than prior-year quarter net loss of $8,316,000. Operating costs rose (notably general & administrative) while…
10-K · March 6, 2025
Theriva Biologics has completed a strategic shift to oncology following its March 2022 acquisition of VCN and is developing the oncolytic adenovirus VCN-01 (administered to 142 patients) with a Phase 2b VIRAGE trial…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.